Results 121 to 130 of about 3,296 (168)

Targeted Inhibition in Pediatric MET and ALK-Altered Hemispheric Gliomas: Objective Responses Followed by Treatment Resistance. [PDF]

Int J Mol Sci
Wilson D, Jayappa S, Parker L, Ocal E, Tanaka T, Gokden M, Bielamowicz K.   +6 more
europepmc   +1 more source

Aminopyridines in the development of drug candidates against protozoan neglected tropical diseases. [PDF]

Future Med Chem
Mustière R, Dassonville-Klimpt A, Sonnet P.   +2 more
europepmc   +1 more source

Research Trends in Chronic Obstructive Pulmonary Disease (2005-2024): From Drug Therapy to Comprehensive Rehabilitation Strategies. [PDF]

Int J Chron Obstruct Pulmon Dis
Zhan M, Chen J, Zhang H.
europepmc   +1 more source

Effects of cAMP and CFTR modulation on apical fluid pH in human airway Calu-3 cells. [PDF]

Physiol Rep
Nguyen JP, Milad N, Hirota JA.
europepmc   +1 more source

Advances in the restoration of CFTR in children and pwCF with "mild disease". [PDF]

Pediatr Pulmonol
Cohen-Cymberknoh M.
europepmc   +1 more source

Abemaciclib-associated acute interstitial nephritis successfully treated with glucocorticoids: a case report and literature review. [PDF]

BMC Nephrol
Kumano M, Maeoka Y, Teragawa Y, Yanagidani H, Yoshida M, Takahashi A, Masaki T.   +6 more
europepmc   +1 more source

Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report. [PDF]

Oncotarget
Wu JL, Iams WT.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

4-Aminopyridine kinetics

Clinical Pharmacology and Therapeutics, 1982
Nine healthy subjects (7 men; 2 women) received single 20-mg IV injections of 4-aminopyridine (4-AP). Six of the subjects received the same dose in the form of enteric-coated tablets and four the same dose in uncoated tablets; treatments were at least 2 wk apart.
UGES, DRA, SOHN, YJ, GREIJDANUS, B, SCAF, AHJ, AGOSTON, S   +4 more
openaire   +3 more sources